Legal Action in Drug Compounding Dispute
Eli Lilly has filed lawsuits against two pharmacies accused of producing modified versions of its medications containing tirzepatide. The companies, Strive Pharmacy and Empower Pharmacy, are alleged to have continued preparing formulations related to its weight loss product Zepbound and the diabetes treatment Mounjaro after guidelines required that such compounding cease.
According to legal documents filed in Delaware and New Jersey this week, the pharmacies are promoting their compounded products as personalized medications that meet the same strict standards as Lilly’s own brands. The filings claim these assertions may mislead patients into choosing these alternatives over fully approved and rigorously tested treatments. Lilly contends that these actions violate current FDA policies now that the shortages of the original branded versions have ended.
The FDA had clearly directed that once the available supply of Lilly’s approved products was sufficient, large-scale compounding of tirzepatide should stop. Notwithstanding this, several facilities continued to adjust dosages and incorporate additives like vitamins in their formulations. Lilly’s suit argues that these practices do not reflect true customization for patients with unique needs—such as allergies or difficulties with the standard dosage form—but instead constitute mass production that bypasses regulatory limits.
Neither Strive Pharmacy nor Empower Pharmacy has offered a comment regarding the lawsuit. The matter has attracted significant attention from industry analysts and regulators focused on upholding compounding standards.
For Lilly, these legal actions represent a critical effort to protect its product reputation and maintain trust in treatments that have undergone extensive clinical evaluation. The decisions made in these cases are expected to influence the broader pharmaceutical market. The outcomes may also affect companies such as Novo Nordisk, whose drugs like Wegovy and Ozempic face similar restrictions on compounding following the resolution of shortages earlier this year. Market watchers suggest a ruling could establish clear guidelines for compounded medications when fully approved alternatives exist.
The case stands as a test of whether companies can continue preparing non-approved versions of key drug components once regulatory shortages have ended, and it may shape future enforcement strategies for compounding pharmacies. Industry analysts are watching these developments closely, expecting the outcome to influence future practices among compounding facilities and regulatory enforcement. The impact of this case remains uncertain.
